Pivotal Trials For EU Approval Still Underrepresent Minorities, Study Finds

Roma, Europe’s Largest Minority, Not Represented At All

The study, by Tufts CSDD, also found that data on minority groups were frequently underreported, and in many cases numbers have not improved with time.

3d render of Europe map Earth globe
A new study by Tufts CSDD shines a light on clinical trial diversity in Europe • Source: Shutterstock

A new study highlights the under-reporting of racial and ethnic data from pivotal trials for drugs that have received approval in Europe, which perhaps is one reason trial diversity has been less in the public spotlight there.

The study, from Tufts University’s Center for the Study of Drug Development (Tufts CSDD), appears in the May/June issue of...

More from Clinical Trials

Four Chinese Firms Snag Global First-In-Class Approvals In China

 

Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By 

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By 

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

ProKidney Pins Hopes On Accelerated Approval For Rilparencel

 

After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.

More from R&D

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By 

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

ProKidney Pins Hopes On Accelerated Approval For Rilparencel

 

After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.

BREAKING NEWS: Merck & Co. Leaps Into COPD Space With $10bn Verona Buy

 
• By 

The UK firm's chronic obstructive pulmonary drug Ohtuvayre has been enjoying a stellar launch.